AzTrials
AzTrials

Peri-implantitisNCT02406001

Reconstruction of Peri-implant Osseous Defects: A Randomized Trial

A study testing Tigran PTG and Surgical intervention in people with Peri-implantitis, run by Tigran Technologies AB at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this randomized trial was to compare reconstructive surgery of advanced peri-implant intra-osseous defects with porous titanium granules (PTG/Test) to open flap debridement (OFD/Control) in a non-submerged technique over 6 months. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Peri-implantitis
What is being tested?
Tigran PTG and Surgical intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteSweden
Study dates
Jun 2010to Jun 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All implants had to be in function for more than 12 months. Only one implant per patient was included in the study.
  • Primary inclusion criteria
  • By initial radiographic evaluation:
  • Intraosseous defect ≥ 3 mm defect depth on standard intraoral radiograph.
  • By clinical evaluation:
  • Peri-implant probing depth (PD) ≥ 5 mm
Show all 13Show fewer
  • Bleeding (BOP) and/or suppuration (PUS)
  • Secondary inclusion criteria
  • By intra-operative exploration:
  • Intra-osseous defect component ≥ 3 mm at the deepest point
  • 3 to 4 wall intra-osseous
  • Osseous defect with at least 270 degrees (circumferential)
  • Defect angle ≤ 35 degrees (from axis of implant)

Who cannot join

  • Subjects with diabetes mellitus (HbA1c ≥6.5)
  • Subjects taking corticosteroids or other anti-inflammatory prescription drugs.
  • Subjects taking medications known to induce gingival hyperplasia
  • Subjects with a history of taking systemic antibiotics in the preceding month.
  • Patients pregnant or nursing
  • Implants placed in grafted bone or previously augmented with bone /bone substitute or other type of regenerative material
Show all 9Show fewer
  • Implants previously surgically treated for peri-implantitis
  • Failure to obtain soft tissue closure
  • Mobile implant

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Tigran Technologies AB

    Malmö, SE 205 12

Other trials in Sweden

About this study

Official title: Reconstructive Surgical Treatment of Peri-implant Intra-osseous Defects - A MULTICENTER RANDOMIZED PROSPECTIVE CLINICAL STUDY

The purpose of this randomized trial was to compare reconstructive surgery of advanced peri-implant intra-osseous defects with porous titanium granules (PTG/Test) to open flap debridement (OFD/Control) in a non-submerged technique over 6 months.

Read the detailed description

Scientific rationale for study:

There is a paucity of data for the effectiveness of reconstructive procedures in the treatment of peri-implantitis. Recently, titanium brushes have been introduced for implant surface debridement and porous titanium granules (PTG) as an osteoconductive bone substitute.

Study design The study was designed as a prospective multicentre, multi-national, randomized, parallel group-controlled clinical trial of 6 months duration.

All participating investigators attended training and calibration meetings to discuss and optimize patient accrual and retention as well as data management. Preliminary clinical cases were discussed to standardize case selection, the measurement techniques and surgical procedures. On-site rules, for the compilation of the data collection sheets for appropriate oversight were frequently reassured by a study monitor to ensure the validity of the data.

Open flap debridement and surface decontamination with titanium brush (n = 30/Control), or additional insertion of PTG (n=33/Test) was performed for reconstruction of 3- or 4-wall intra-osseous peri-implant defects with at least 3 mm defect depth and circumferential (≥270°) morphology. Patients were given amoxicillin and metronidazole for 8 days. Radiographic and clinical assessments were performed at baseline and 6 months.

Study population Study subjects were recruited consecutively from patients treated by dental specialists in periodontology or implantology in Germany (University of Bonn), the Netherlands (Amsterdam), Italy (Rome University), Spain (University Madrid) and Sweden (Kristianstad University). Each participant signed an informed consent in accordance with the Helsinki Declaration of 1975 as revised in 2008. The Ethical Committee for human subject trials in each institution approved the study protocol individually. Seventy informed and consenting patients above the age of 18 years of age with a diagnosis of peri-implantitis were enrolled in the study and surgery was performed.

Pre-surgical treatment and evaluation Clinical screening included medical history, physical examination and admission criteria. All necessary endodontic and periodontal treatments were finished as evaluated with recording of pocket probing depth (PPD), inflammation (BoP) and plaque at least 1 month prior to the peri-implant surgical procedure and to entry into the study. Potential prosthetic factors to the aetiology of the disease process were resolved prior to study treatment.

Patients who met all criteria for inclusion, verified at surgery, underwent baseline measurements and investigational procedures.

Clinical measurements Baseline measurements at the included implant site were performed on the same day as the surgical procedure. All probing measurements were obtained with a pressure (0.20-0.25N) sensitive probe (Click-Probe®, Kerr, Switzerland) to the nearest mm at 6 sites per tooth/implant (mesio-buccal, buccal, disto-buccal, disto-palatal, palatal, mesio-palatal).

At baseline and 6-months visits, the following recordings were taken:

  • Probing pocket depths (PPD)
  • Bleeding on probing (BoP)
  • Suppuration (PUS)
  • Plaque BoP and PUS at the affected implant sites were assessed within 30 seconds following probing of the pocket/implant mucosa.

Intraoperative measurements during surgery

  • Intra-osseous defect component (mm) at the deepest point.
  • Circumference of the osseous defect (degrees), 3 or 4 wall intra-osseous component.
  • Defect width (mm).

Radiographic measurements Intra-oral peri-apical radiographs were obtained using a reproducible technique with standard Eggen holders and long cone equipped dental X-ray units. All radiographs presenting study implants were digitalized, coded and evaluated by a computer program (MATLAB® Vers. R2013b software for MAC OS 10.9; Mathworks, Natick, MA, USA).

Radiographs were studied by changing parameters in black and white modus as well as in colour look-up tables. Measurements from a well defined reference point at the coronal part of the implant body taken at baseline and 6-months visits were: vertical defect depth and width, marginal bone level and horizontal bone level. Based on these measurements, changes in vertical defect depth, marginal bone level, % defect fill and % defect resolution from baseline to 6 month were calculated.

The most coronal confluent aggregation of bone or graft material was used to define bone levels. Single isles of bone or bone-like material were not considered.

Implant length and width or known dimensions of implant-threads were used as reference for calibration of measurements. The implant abutment interface served as well defined landmark reference for follow-up recordings. Radiographic evaluations were performed by a physicist trained on sample images on a LCD-display with a resolution of 2560 x 1600 and a 32-Bit colour pixel depth and two periodontists.

Sample size calculation/Power analysis The calculation of patients to be treated (sample size) was based on a previous proof-of-concept single-centre RCT (Wohlfahrt et al. 2012) and the primary objective to detect a true mean difference of at least 2 mm between test and control treatment for radiographic defect fill after 6 months. With a level of significance of alpha = 0.05 in a two-sided hypothesis and a power of 90 %, the number of patients needed was 48. Assuming a dropout rate of about 30% the total number of patients required was 60.

Randomization, Allocation Concealment and Blinding Patients were randomly assigned to treatment modality by using a randomization scheme prepared prior to study initiation and to treatment in blocks of 6. The patients were allocated to either reconstruction of the defect with PTG (Test group) or closure of the flap after implant debridement (OFD/Control). Documentation of treatment allocation for each patient was placed in separate, sealed opaque envelopes that were opened and revealed to the surgeon after debridement of the defect and implant surface was finished. Clinical examiners remained blinded to the treatment assigned.

Interventions Pre-Surgical Phase All patients had a full periodontal examination with probing of pocket depth (PPD) and registration of full mouth bleeding and plaque scores. Pre-surgical interventions included oral hygiene instructions to the individual needs of the patient and a complete non-surgical and surgical periodontal treatment.

Surgical Procedure A non-submerged surgical technique was used for both experimental and control sites. Following administration of local anaesthesia flap elevation procedure included an intra-crevicular incision around the implant. Full thickness mucoperiosteal flaps were raised on the buccal and lingual aspect to gain access to the complete peri-implant defect and to the implant surface. The extent of this incision was determined by supra-crestal incisions extending mesial and distal of the implant site. Vertical incisions into the vestibule at a distance of at least one tooth/implant from the implant were performed as necessary for adequate access. Granulation tissue was removed using titanium curettes (HuFriedy®, Chicago, IL, USA) and the exposed implant surfaces were cleaned mechanically by using a rotary titanium brush (Tigran PeriBrush™, Tigran Technologies, Malmö, Sweden) and decontaminated chemically with 3% H2O2 for 1 minute followed by rinsing with saline for 60 seconds (2 x 20 ml).

Following treatment allocation in accordance to randomization, titanium granules (Tigran™, Tigran Technologies, Malmö, Sweden) were applied into the osseous defects of the test sites. After insertion of the granules, excess material was carefully removed. Flaps were then repositioned and sutured back into position using monofilament non-resorbable sutures.

Peri-operative protocol Patients were prescribed a combination of Amoxicillin 500 mg 3/day for 8 days and Metronidazole 400 mg 2/day for 8 days, starting one day prior to surgery. Patients were then instructed to rinse twice daily with chlorhexidine mouth rinse (0.2%) for 1 month. The patients used brushes as usual in other areas of the mouth. Anti-inflammatory and analgesic therapy was prescribed (Ibuprofen 3 x 600 mg/day) during the first two days and according to the individual needs thereafter.

The sutures were removed after 7 to 14 days and patients were instructed in the use of soft toothbrushes and soft interdental brushes (super soft - Gentle/Implant Care TePe, Malmö, Sweden) in the surgical area.

Patients were recalled at 6 weeks, 3, 6 months after surgery for professional oral hygiene procedures with individually based supra-gingival debridement and hygiene instructions as needed.

Early withdrawal criteria:

  • non healing infections
  • substantial exfoliation of graft material (rejection)
  • local intolerance to graft material
  • recurrence of active peri-implantitis at the test site
  • loosening of implant
  • poor patient cooperation, not returning for control visits

Statistical Analysis Statistical analysis of primary efficacy endpoint was performed using stratified Wilcoxon test, using centre as stratification variable.

Treatment intergroup comparisons of secondary efficacy endpoints were based on least squares means obtained from the ANCOVA model. Least-square means for each treatment group and differences in least-squares means between treatment groups are presented along with associated 95% Confidence Intervals (CI) as well as p-values for differences within treatment groups.

All analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

The statistical hypotheses for the Primary Objective was:

H0: Δ bone level Test - Δ bone level Control = 0 H1: Δ bone level Test - Δ bone level Control ≠ 0

For percent changes the statistical hypotheses was based on:

  • Defect resolution=(Vertical defect baseline- Vertical defect 6months)/( Vertical defect baseline) x100
  • Defect Fill = (Marginal bone level baseline- Marginal bone level 6months )/( Vertical defect baseline) x100

If the p-value from this analysis fell below 0.05 in both mesial and distal measurements it was concluded that there was a statistically significant difference in average change between the two treatment groups.

Being tested
Tigran PTG, Surgical intervention
Keywords
peri-implantitis, osseous defects, implant surface decontamination, bone grafting, surgical therapy, porous titanium granules, reconstruction
Medical subject headings
Peri-Implantitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tigran PTGDevice

    Open Flap Debridement

  • Surgical interventionProcedure or surgery

    Open Flap Debridement

Study groups in NCT02406001
Study groupRoleWhat they receive
Tigran PTGExperimentalSurgical intervention: open flap debridement and implantation of bone grafting material
Receives: Device: Tigran PTG; Procedure: Surgical intervention
ControlOtherSurgical intervention: open flap debridement
Receives: Procedure: Surgical intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. changes in radiographic bone level (mm)

    Measured: baseline and 6 month after treatment

Secondary outcomes (6)
  1. % radiographic defect fill

    Measured: baseline and 6 month after treatment

  2. % radiographic defect resolution

    Measured: baseline and 6 month after treatment

  3. Pocket Probing Depth (PPD)

    Measured: baseline and 6 month after treatment

  4. Bleeding on Probing (BoP)

    Measured: baseline and 6 month after treatment

  5. Suppuration (PUS)

    Measured: baseline and 6 month after treatment

  6. Plaque

    Measured: baseline and 6 month after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2015 (estimated)
  2. Study startJun 2010
  3. Primary completionJan 2014
  4. Study completionJun 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02406001
Sponsor's protocol ID
TIG08-002
Status last verified
Mar 2015
First submitted
9 Dec 2014
Last updated
1 Apr 2015
Results posted
No
Data monitoring committee
Yes

Publications

  • Chan HL, Lin GH, Suarez F, MacEachern M, Wang HL. Surgical management of peri-implantitis: a systematic review and meta-analysis of treatment outcomes. J Periodontol. 2014 Aug;85(8):1027-41. doi: 10.1902/jop.2013.130563. Epub 2013 Nov 21.

    PubMed 24261909
  • Khoshkam V, Chan HL, Lin GH, MacEachern MP, Monje A, Suarez F, Giannobile WV, Wang HL. Reconstructive procedures for treating peri-implantitis: a systematic review. J Dent Res. 2013 Dec;92(12 Suppl):131S-8S. doi: 10.1177/0022034513509279. Epub 2013 Oct 24.

    PubMed 24158331
  • Jepsen K, Jepsen S, Laine ML, Anssari Moin D, Pilloni A, Zeza B, Sanz M, Ortiz-Vigon A, Roos-Jansaker AM, Renvert S. Reconstruction of Peri-implant Osseous Defects: A Multicenter Randomized Trial. J Dent Res. 2016 Jan;95(1):58-66. doi: 10.1177/0022034515610056. Epub 2015 Oct 8.

    PubMed 26450511

Questions about this trial

What is this clinical trial studying?

A study testing Tigran PTG and Surgical intervention in people with Peri-implantitis, run by Tigran Technologies AB at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

changes in radiographic bone level (mm) (time frame: baseline and 6 month after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02406001, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in